logo

FDA Calendar

Share
Company Name Vertex Pharmaceuticals Inc.
Drug Name KALYDECO (sNDA)
Event Name FDA decision on KALYDECO for the treatment of cystic fibrosis patients with additional rare CFTR mutations
Event Date 12/30/2020
Outcome Date
Outcome
Drug Status
Rival Drugs
Market Potential
Other Approvals KALYDECO is already approved for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have at least one mutation in their CF gene that is responsive to KALYDECO
News
Return to FDA Calendar